Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue.

Ferreira RA, Vieira CS, Rosa-E-Silva JC, Rosa-e-Silva AC, Nogueira AA, Ferriani RA

Contraception16 Sept 2009Cited by 38 (Europe PMC)

PMID20103448DOI10.1016/j.contraception.2009.08.003PepBankPUB-20103448

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with endometriosis, pain decreased in both groups, with no significant difference between leuprolide and the levonorgestrel intrauterine system.
In plain wordsIn women with endometriosis, pain decreased similarly with leuprolide and the levonorgestrel intrauterine system.
Peptide
Leuprolide
Outcome
No significant changePain score
Study
n = 44
Comparator
Levonorgestrel intrauterine system
Outcome group
Pain · Reproductive and sexual health
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of treatment, a significant reduction in pain score occurred in both groups with no significant difference in improvement between the two medications evaluated.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, prospective, open clinical study, with 44 patients with laparoscopically and histologically confirmed endometriosis.
Summary · context
Patients were randomized into two groups: the LNG-IUS group, composed of 22 patients who underwent LNG-IUS insertion, and the GnRHa group, composed of 22 patients who received a monthly GnRHa injection for 6 months.
Report a problemFND-2010344801
02HumanNon-randomized trialEfficacy outcome
In women with endometriosis, homocysteine increased from 11.5+/-2.9 to 13.0+/-2.7 mumol/L during leuprolide treatment (p=.04).
In plain wordsIn women with endometriosis, homocysteine increased from 11.5 to 13.0 mumol/L during leuprolide treatment.
Peptide
Leuprolide
Outcome
IncreaseHomocysteine
Study
n = 22
Outcome group
Cardiovascular Risk Markers · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Homocysteine before treatment
11.5 mumol/L
GnRHa group; SD 2.9
Homocysteine after 6 months
13 mumol/L
GnRHa group; SD 2.7
P value
0.04
GnRHa group, before versus after
Source sentences
Summary
The GnRHa group showed an increase in HMC levels (11.5+/-2.9 to 13.0+/-2.7 mumol/L, p=.04)
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, prospective, open clinical study, with 44 patients with laparoscopically and histologically confirmed endometriosis.
Summary · context
Patients were randomized into two groups: the LNG-IUS group, composed of 22 patients who underwent LNG-IUS insertion, and the GnRHa group, composed of 22 patients who received a monthly GnRHa injection for 6 months.
Report a problemFND-2010344802
03HumanNon-randomized trialEfficacy outcome
In women with endometriosis, IL-6 decreased from 4.3+/-3.9 to 2.3+/-0.8 pg/mL during leuprolide treatment (p=.005).
In plain wordsIn women with endometriosis, IL-6 decreased from 4.3 to 2.3 pg/mL during leuprolide treatment.
Peptide
Leuprolide
Outcome
DecreaseInterleukin-6
Study
n = 22
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
IL-6 before treatment
4.3 pg/mL
GnRHa group; SD 3.9
IL-6 after 6 months
2.3 pg/mL
GnRHa group; SD 0.8
P value
0.005
GnRHa group, before versus after
Source sentences
Summary
The GnRHa group showed an increase in HMC levels (11.5+/-2.9 to 13.0+/-2.7 mumol/L, p=.04) and a reduction in IL-6 levels (4.3+/-3.9 to 2.3+/-0.8 pg/mL, p=.005), VCAM (94.0+/-3.8 to 92.0+/-1.6 ng/mL, p=.03) and total leukocytes (7330+/-2554 to 6350+/-1778, p=.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, prospective, open clinical study, with 44 patients with laparoscopically and histologically confirmed endometriosis.
Summary · context
Patients were randomized into two groups: the LNG-IUS group, composed of 22 patients who underwent LNG-IUS insertion, and the GnRHa group, composed of 22 patients who received a monthly GnRHa injection for 6 months.
Report a problemFND-2010344803
04HumanNon-randomized trialEfficacy outcome
In women with endometriosis, VCAM decreased from 94.0+/-3.8 to 92.0+/-1.6 ng/mL during leuprolide treatment (p=.03).
In plain wordsIn women with endometriosis, VCAM decreased from 94.0 to 92.0 ng/mL during leuprolide treatment.
Peptide
Leuprolide
Outcome
DecreaseVascular cell adhesion molecule
Study
n = 22
Outcome group
Cardiovascular Risk Markers · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
VCAM before treatment
94 ng/mL
GnRHa group; SD 3.8
VCAM after 6 months
92 ng/mL
GnRHa group; SD 1.6
P value
0.03
GnRHa group, before versus after
Source sentences
Summary
The GnRHa group showed an increase in HMC levels (11.5+/-2.9 to 13.0+/-2.7 mumol/L, p=.04) and a reduction in IL-6 levels (4.3+/-3.9 to 2.3+/-0.8 pg/mL, p=.005), VCAM (94.0+/-3.8 to 92.0+/-1.6 ng/mL, p=.03) and total leukocytes (7330+/-2554 to 6350+/-1778, p=.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, prospective, open clinical study, with 44 patients with laparoscopically and histologically confirmed endometriosis.
Summary · context
Patients were randomized into two groups: the LNG-IUS group, composed of 22 patients who underwent LNG-IUS insertion, and the GnRHa group, composed of 22 patients who received a monthly GnRHa injection for 6 months.
Report a problemFND-2010344804
05HumanNon-randomized trialEfficacy outcome
In women with endometriosis, total leukocytes decreased from 7330+/-2554 to 6350+/-1778 during leuprolide treatment (p=.01).
In plain wordsIn women with endometriosis, total leukocytes decreased from 7330 to 6350 during leuprolide treatment.
Peptide
Leuprolide
Outcome
DecreaseTotal leukocytes
Study
n = 22
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Total leukocytes before treatment
7330
GnRHa group; SD 2554
Total leukocytes after 6 months
6350
GnRHa group; SD 1778
P value
0.01
GnRHa group, before versus after
Source sentences
Summary
The GnRHa group showed an increase in HMC levels (11.5+/-2.9 to 13.0+/-2.7 mumol/L, p=.04) and a reduction in IL-6 levels (4.3+/-3.9 to 2.3+/-0.8 pg/mL, p=.005), VCAM (94.0+/-3.8 to 92.0+/-1.6 ng/mL, p=.03) and total leukocytes (7330+/-2554 to 6350+/-1778, p=.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, prospective, open clinical study, with 44 patients with laparoscopically and histologically confirmed endometriosis.
Summary · context
Patients were randomized into two groups: the LNG-IUS group, composed of 22 patients who underwent LNG-IUS insertion, and the GnRHa group, composed of 22 patients who received a monthly GnRHa injection for 6 months.
Report a problemFND-2010344805
06HumanNon-randomized trialEfficacy outcome
In women with endometriosis, the remaining measured variables, including lipid profile, did not change significantly during leuprolide treatment.
In plain wordsIn women with endometriosis, the remaining measured variables, including blood lipids, did not change significantly during leuprolide treatment.
Peptide
Leuprolide
Outcome
No significant changeRemaining cardiovascular risk variables including lipids
Study
n = 22
Outcome group
Cardiovascular Risk Markers · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
In the GnRH group, the remaining variables, including lipid profile, did not show any statistical difference.
3 context sentences(design, population, supporting numbers)
Summary · context
Body mass index; systolic and diastolic arterial blood pressure; heart rate; and laboratory cardiovascular risk markers such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), homocysteine (HMC), lipid profile, total leukocytes and vascular cell adhesion mole…
Summary · context
This was a randomized, prospective, open clinical study, with 44 patients with laparoscopically and histologically confirmed endometriosis.
Summary · context
Patients were randomized into two groups: the LNG-IUS group, composed of 22 patients who underwent LNG-IUS insertion, and the GnRHa group, composed of 22 patients who received a monthly GnRHa injection for 6 months.
Report a problemFND-2010344806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.